Sumitomo Dainippon Pharma

Osaka, Japan· Est. 2020

A Japanese pharmaceutical company developing innovative therapies in neuroscience, oncology, and regenerative medicine, with a focus on small molecules and iPS cell-derived cell therapies.

sumitomo-pharma.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

A Japanese pharmaceutical company developing innovative therapies in neuroscience, oncology, and regenerative medicine, with a focus on small molecules and iPS cell-derived cell therapies.

NeuroscienceOncologyRare Disease

Technology Platform

The company utilizes a dual-modality platform focusing on small molecule drug discovery and regenerative medicine/cell therapy, with a specialized capability in allogeneic induced pluripotent stem (iPS) cell-derived product development.

Opportunities

Growth opportunities include the commercial launch and market penetration of its pioneering iPS cell-derived therapy AMCHEPRY, lifecycle management and geographic expansion for its established neuroscience products, and advancing its oncology pipeline.

Risk Factors

Key risks include the execution challenges and high costs associated with commercializing novel cell therapies, potential competition in core therapeutic areas, and the need for successful integration of its global operations and strategic realignments.

Competitive Landscape

In neuroscience and oncology, it competes with global pharmaceutical companies, while in iPS cell-based regenerative medicine, it faces competition from other biotechs and research institutions, differentiating itself through integrated R&D and an early approved product in Japan.

More companies in Japan →